METTL22

Across TCGA pan-cancer cohorts, METTL22 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated METTL22 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher METTL22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated METTL22 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

THYM, LUAD, and STAD are the cancer types where METTL22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
LUAD	DFS	Median	All	0.200	0.816	<.001	20	view →
STAD	OS	Median	All	0.250	0.729	.028	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.668	.029	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

METTL22–THYM (OS)

Open the THYM breakdown →